Over 90 Total Lots Up For Auction at One Location - WA 04/08

Lucida Medical receives CE marking for Pi, its AI-machine learning software for detecting prostate cancer from MR

Press releases may be edited for formatting or style | June 02, 2021 Artificial Intelligence MRI
Cambridge, UK – 1 June 2021: Lucida Medical Ltd, the Cambridge, UK based start-up, has completed CE marking for its new machine learning-based prostate cancer detection software, Prostate Intelligence™ (Pi™). Lucida is one of the first companies in the world to commercialise artificial intelligence software to identify cancer in prostate MRI scans. This crucial milestone enables the cutting-edge technology to be deployed within the UK’s National Health Service (NHS) and European healthcare systems.

Lucida Medical’s goal is to significantly improve the prostate cancer diagnostic pathway with technology that finds cancer more accurately by analysing MRI, enabling radiologists to save time and patients to receive the best possible diagnosis and treatment. It will help providers offer RAPID ‘one stop shop’ diagnosis, enabling patients to have an MRI, report and biopsy in one visit, and ensure consistent reporting quality across imaging networks.

CE marking allows Pi™ to help radiologists assess and report MRI imaging studies, support the decision whether or not to biopsy, and accurately target biopsies where needed. Prostate cancer is the most common cancer in men in Europe, Africa and North and South America, with 1.4 million diagnosed worldwide each year and 375,000 deaths. Earlier detection can help reduce rates of advanced and metastatic disease and in turn greatly improve patients’ experience, outcomes, and life expectancy.
stats
DOTmed text ad

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

stats
Lucida Medical’s Prostate Intelligence™ technology uses radiogenomics, machine learning and image processing to analyse magnetic resonance imaging (MRI) scans. Results presented at the European Congress of Radiology (ECR) in March 2021 indicate that it can help automate labour-intensive tasks such as marking out lesions, and avoid unnecessary invasive biopsies, with unprecedented accuracy and consistency.

MRI is now the preferred technique to assess a range of cancers, including prostate and metastatic disease. However, the current process of radiologists interpreting oncological MRI requires specialist training and is labour-intensive, creating a growing skills challenge. The shortfall in the UK radiologist workforce is forecast to reach 43% by 2024.

Prostate cancer diagnosis using MRI represents a major step forward compared to earlier methods but remains prone to human error. The ground-breaking PROMIS study (Lancet 2017; 389: 815–22) indicated that radiologists can miss 12% of significant cancers on MRI, and lead to 55% of individuals without significant cancer receiving a painful and costly biopsy. The study presented at ECR 2021 suggests that Lucida Medical’s AI technology could help cut missed cancers to 7% and unnecessary biopsies to 24%, as well as making the process faster.

You Must Be Logged In To Post A Comment